Imatinib mesylate for the treatment of steroid-refractory sclerotic-type cutaneous chronic graft-versus-host disease

Sclerotic skin manifestations of chronic graft-versus-host disease (ScGVHD) lead to significant morbidity, including functional disability from joint range of motion (ROM) restriction. No superior second-line therapy has been established for steroid-refractory disease. Imatinib mesylate is a multi-k...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Biol Blood Marrow Transplant
Main Authors: Baird, Kristin, Comis, Leora E., Joe, Galen O., Steinberg, Seth M., Hakim, Fran T., Rose, Jeremy J., Mitchell, Sandra A., Pavletic, Steven Z., Figg, William D., Yao, Lawrence, Flanders, Kathleen C., Takebe, Naoko, Sarantopoulos, Stefanie, Booher, Susan, Cowen, Edward W.
Format: Artigo
Jezik:Inglês
Izdano: 2015
Teme:
Article
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC4425991/
https://ncbi.nlm.nih.gov/pubmed/25771402
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.bbmt.2015.03.006
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki